earticle

영어

Hepatocellular carcinoma (HCC) is one of the most deadly cancers in the world. When HCC is diagnosed in the later stage, there is very poor with a 5-year survival rate than 10%-15%. Thus, accurate test for early diagnosis of HCC would significantly improve the clinical outcome of liver cancer. Currently, early diagnosis of HCC is used to measure method as the identification of alpha-fetoprotein (AFP) expression level in serum using AFP antibody. But, the identification and production of AFP antibodies are onerous, and AFP antibodies are also sensitive to temperature. Therefore, new substitutive molecule that can specifically replace AFP antibodies is needed. This study focused on development of aptamer-based AFP detection assay for HCC early diagnosis. AFP aptamers are generated through an in vitro selection process called systematic evolution of ligands by exponential enrichment (SELEX). After 10 rounds of selection, affinity test and interaction between AFP and AFP antibody were performed. These results demonstrate that AFP binding DNA aptamers have high affinity interaction (8.87x10-11) and inhibit interaction between AFP and AFP antibody. Hence, AFP aptamer is adaptable to novel substitution for detecting HCC by binding AFP.